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Abstract
Background: Melanoma accounts for the majority of skin cancer deaths. It has over thirty different subtypes.
Different races have been observed to differ in multiple aspects of melanoma.
Methods: SEER (Surveillance, Epidemiology, and End Results) data on six major subtypes, namely melanoma in situ
(MIS), superficial spreading melanoma (SSM), nodular melanoma (NM), lentigo maligna melanoma (LMM), acral
lentiginous melanoma malignant (ALM), and malignant melanoma NOS (NOS), were analyzed. The racial groups
studied included NHW (non-Hispanic white), HW (Hispanic white), Black, and Asian/PI (Pacific Islanders). Univariate
and multivariate analysis was conducted to quantify racial differences in patients’ characteristics, incidence,
treatment, and survival.
Results: Significant racial differences are observed in patients’ characteristics. For all subtypes except for ALM,
NHWs have the highest incidence rates, followed by HWs, while Blacks have the lowest. For ALM, HWs have the
highest rate, followed by NHWs. In stratified analysis, interaction between gender and race is observed. For the first
five subtypes and localized and regional NOS, the dominating majority of patients had surgery, while for distant
NOS, the distribution of treatment is more scattered. Significant racial differences are observed for distant ALM and
NOS. For MIS, SSM, NM, LMM, and ALM, there is no significant racial difference in survival. For NOS, significant racial
differences in survival are observed for the localized and regional stages, with NHWs having the best and Blacks
having the worst five-year survival rates.
Conclusions: Racial differences exist for the six major melanoma subtypes in the U.S. More data collection and
analysis are needed to fully describe and interpret the differences across racial groups and across subtypes.
Keywords: Melanoma, Racial difference, Subtype, SEER
Abbreviations: ALM, Acral lentiginous melanoma malignant; Asian/PI, Asian and Pacific Islanders; HW, Hispanic
white; LMM, Lentigo maligna melanoma; MIS, Melanoma in situ; NHW, Non-Hispanic white; NM, Nodular melanoma;
NOS, Malignant melanoma NOS; SSM, Superficial spreading melanoma
Background
Melanoma is the most dangerous type of skin cancer. In
2015, it is estimated that there were 73,870 new cases,
and an estimated 9,940 people died of this disease [1]. It
represents 4.5 % of all new cancer cases. The incidence
of melanoma has been steadily rising since 1975 in the
U.S. [2]. Melanoma has over thirty different subtypes
with significantly different behaviors. In this article, the
focus is on the following six most major subtypes.
Melanoma in site (MIS) is an early form of melanoma
with atypical melanocytes confined to the epidermis.
Superficial spreading melanoma (SSM) is more common
for the 30–50 years old, often on the trunk, and in
women often on the legs. Nodular melanoma (NM) is
more common for the 40–60 years old and twice as com-
mon in men. It has no horizontal growth phase and rapid
vertical growth. Lentigo maligna melanoma (LMM) is
more common for the 50–80 years old, especially with
sun-damaged skin. It develops on the face in 90 % of
cases. Acral lentiginous melanoma (ALM) presents up to
75 % of melanomas in non-Caucasian patients and occurs
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on acral surfaces. The last major subtype studied is malig-
nant melanoma, NOS.
It has been suggested that there exist racial differences
in multiple aspects of melanoma. Overall, Whites have a
higher risk and poorer prognosis. Melanoma occurs
more commonly in unusual anatomic sites (e.g., palms
and soles) in minority populations than in Whites [3].
With rare occurrence and unusual presentation, the
diagnosis of melanoma is often delayed in minorities,
leading to more advanced stages. A few studies have
been conducted, examining racial difference in melan-
oma. Examples include that by Du and others [4], which
linked the NLMS (National Longitudinal Mortality Stud-
ies) and SEER (Surveillance, Epidemiology, and End Re-
sults) databases and examined the effects of individual-
level socioeconomic factors on racial disparities in re-
ceiving treatment and survival. Another study examined
racial differences in overall and melanoma-specific sur-
vival, stratified by receipt of surgical treatment and by
specific types of surgical treatment [5]. Cormier and
others [6] analyzed SEER data and quantified racial dif-
ferences in clinicopathologic factors and survival for cu-
taneous melanoma patients. Results in the literature
have not always been consistent. For example, Reintgen
and others [7] reported differences in stage-specific
melanoma outcomes between Blacks and Whites, how-
ever, Hemmings and others [8] reported no differences
in outcomes in non-Whites versus Whites who were
stratified by stage at initial diagnosis.
Despite the aforementioned efforts, to date, racial
differences in melanoma still have not received suffi-
cient attention. The goal of this study is to fill this
knowledge gap and systematically describe racial
differences for the six most major subtypes of melan-
oma using SEER data. Studying racial difference can
assist better diagnosis, tailored treatment, and elimin-
ation of racial disparity. Analyzing and directly com-
paring multiple subtypes can provide valuable insights
beyond single-subtype analysis [9]. This study differs
from and complements the existing literature in mul-
tiple aspects. First, it analyzes the six major subtypes
separately and can better accommodate cancer hetero-
geneity than studies that analyze melanoma overall
[10]. Second, it analyzes patient characteristics, inci-
dence, treatment, as well as survival for four major ra-
cial groups, and can be more comprehensive than
those that focus on one specific aspect and fewer
racial groups [5]. Third, different subtypes are ana-
lyzed on the same ground using the same techniques.
Some of the existing studies have also conducted sub-
type analysis [9]. However, as they analyzed different
study populations and adopted different statistical




The population-based sample was obtained from SEER
(Surveillance, Epidemiology, and End Results) [11], which
is the most comprehensive population-based cancer data-
base in the U.S., containing data from eighteen regional
and state registries. SEER has multiple registry groupings
for analysis, which cover different numbers of regions and
different time period. SEER 9, 13, and 18, which are ana-
lyzed in this study, cover approximately 9.5, 14, and 28 %
of the U.S. population, respectively [12].
For each case, the first matching record was identified
for analysis. Incident cases of melanoma of the skin – de-
fined using ICD-O-3 site codes C440-449 and histology
codes 8720-8790 – were selected. The histology codes
were grouped for analysis as follows: MIS (ICD-O-3 code
8720/2), NM (ICD-O-3 code 8721/3), LMM (ICD-O-3
code 8742/3), SSM (ICD-O-3 code 8743/3), ALM (ICD-
O-3 code 8744/3), and NOS (ICD-O-3 code 8720/3).
Different registry groupings were used for different
analysis to maximize sample size. Specifically, for the
analysis of patients’ clinicopathologic features, SEER 9
contains data on cancers diagnosed between 1973 and
2011. Information is available on gender, marital status,
age at diagnosis, age group, anatomic site, thickness of
tumor, presence of satellite nodules, ulceration, lymph
node extension, stage, treatment, and type of surgery.
More details are available in Table 1. The variable “ana-
tomic sites” is defined using ICD-O-3 [13]. Anatomic
body sites include skin of the face, head, and neck
(C44.0–44.4), trunk (C44.5, including back, abdomen,
and chest), upper extremity (C44.6), lower extremity
(C44.7), and all “other or unknown” body sites which are
combined into a single category. Four variables, includ-
ing “satellite tumors” (1973–1982), “4-Digit Extent of
Disease (EOD 4)-extension” (1983–1987), “10-Digit Ex-
tent of Disease (EOD 10)-extension” (1988–2003) and
“clinical stage (CS) lymph nodes” (2004), are recoded to
form the three-category satellite nodule variable. Three
variables, including “type of melanoma” (1973–1982),
“extension” (1988–2003), and “CS site specific factor 2
ulceration” (2004), are recoded to form the three-
category skin ulceration variable. Skin ulceration status
was not coded between 1983 and 1987, therefore, all
1983–1987 cases are coded as having “unknown” for ul-
ceration. Five variables, including “regional lymph node
involvement” (1973–1982), “distant lymph nodes”
(1973–1982), “EOD 4 lymph nodes” (1983–1997), “EOD
10 lymph nodes” (1988–2003), “CS lymph nodes” (2004),
are recoded to categorize the extent of lymph node in-
volvement. Treatment is analyzed both as a patient’s
characteristic and as a cancer response variable. For mel-
anoma, removal by surgery is the most common treat-
ment. Other options include immunotherapy, biologic
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Table 1 Patients’ characteristics and clinicopathologic features


























Gender <0.001 <0.001 <0.001
Male 54.7 36.0 45.0 44.6 53.3 35.6 42.2 49.2 61.6 51.8 44.3 56.3
Female 45.3 64.0 55.0 55.4 46.7 64.4 57.8 50.8 38.4 48.2 55.7 43.8
Marital Status <0.001 <0.001 <0.001
Single 12.6 15.4 22.1 18.8 15.4 18.8 26.3 23.9 14.9 21.3 37.0 17.6




13.5 13.8 23.3 13.5 13.4 13.5 25.6 13.4 21.6 20.2 28.3 20.4
Age at
diagnosis
60.5 ± 15.9 55.6 ± 16.9 59.2 ± 16.2 55.0 ± 17.9 <0.001 54.7 ± 16.7 49.2 ± 16.5 56.0 ± 17.7 52.7 ± 17.3 <0.001 62.1 ± 17.7 55.9 ± 19.1 62.7 ± 18.1 60.3 ± 20.1 <0.001
Anatomic Site <0.001 <0.001 <0.001
Face/head/
neck
25.7 28.6 18.0 22.3 13.7 14.4 9.6 11.0 22.9 22.5 15.1 16.9
Trunk 30.9 24.1 12.6 26.0 39.0 33.9 29.8 36.0 32.1 28.3 18.9 26.3
Upper
Extremity
25.9 23.9 24.8 22.8 25.7 22.9 17.0 18.7 27.1 20.8 12.3 13.8
Lower
Extremity
17.0 23.0 44.1 29.0 21.0 28.4 42.2 33.5 17.4 28.0 51.9 43.1
Other 0.6 0.5 0.5 0 0.5 0.4 1.4 0.8 0.6 0.4 1.9 0
Thickness of
tumor (mm)
0.80 ± 1.83 0.78 ± 1.85 1.02 ± 1.31 0.68 ± 0.88 0.980 0.92 ± 1.09 1.01 ± 1.20 1.51 ± 2.11 1.36 ± 1.96 <0.001 3.27 ± 2.51 3.93 ± 3.02 4.22 ± 3.18 4.23 ± 3.04 <0.001
Satellite nodules 0.012 0.280
No - - - - 97.0 97.2 95.9 95.3 93.5 93.9 88.7 95.6
Yes - - - - 0.6 1.1 0.9 0.8 3.6 3.5 4.7 3.1
Unknown - - - - 2.4 1.7 3.2 3.8 3.0 2.6 6.6 1.3
Ulceration 0.242 0.001 0.001
No 92.2 91.7 94.1 91.1 86.7 87.6 83.5 87.4 59.8 56.0 50.9 56.3
Yes 0.5 0.4 0.9 0 4.9 6.0 8.3 6.6 31.4 38.3 37.7 35.6




None 99.9 99.8 99.5 100.0 72.7 78.8 67.0 76.9 63.3 60.4 52.8 58.1
Regional 0 0 0 0 3.2 4.7 5.0 6.6 16.6 25.3 18.9 25.0
Distant 0 0 0 0 0.1 0.2 0 0 0.9 2.0 5.7 1.9












Table 1 Patients’ characteristics and clinicopathologic features (Continued)
Stage 0.996 <0.001 <0.001
In situ 100.0 100.0 100.0 100.0 - - - - - - - -
Localized - - - - 92.7 90.8 86.7 87.9 62.1 51.1 43.4 52.5
Regional - - - - 5.4 7.4 9.6 9.6 32.0 40.1 38.7 41.3
Distant - - - - 0.4 0.8 0.9 0.8 4.1 7.1 14.2 5.6
Unstaged 0.0 - - - 1.5 1.1 2.8 1.6 1.9 1.7 3.8 0.6
Treatment 0.152 0.005 0.033
No treatment 4.1 5.8 5.0 4.2 1.6 2.0 1.4 2.2 1.5 1.6 1.9 1.3
Surgery 95.1 93.7 94.6 95.3 97.1 97.1 95.4 95.6 94.7 94.8 90.6 93.8
Radiation 0.1 0.1 0 0.2 0.1 0 0.5 0 0.2 0 0 1.3
Radiation &
Surgery
0.4 0.3 0 0 0.9 0.8 1.4 1.9 3.3 3.2 5.7 3.1
Unknown 0.2 0.2 0.5 0.2 0.4 0.1 1.4 0.3 0.4 0.4 1.9 0.6
Type of surgery <0.001 <0.001 <0.001
No surgery 4.2 5.9 5.1 4.5 1.7 2.1 1.6 2.3 1.8 1.7 2.0 2.1
Biopsy 65.8 63.9 51.6 55.8 43.0 43.6 37.0 42.9 32.5 35.1 34.3 32.9
Wide excision 29.8 29.9 40.0 39.3 55.0 53.5 59.3 54.2 64.3 57.3 57.6 60.3
Amputation 0.1 0.2 2.8 0.5 0.1 0.4 2.1 0.3 0.5 3.5 3.0 4.1
Surgery NOS 0.1 0.1 0.5 0 0.3 0.5 0 0.3 0.9 2.4 3.0 0.7
Survival
time (month)
300.7 ± 3.0 355.9 ± 13.1 287.8 ± 15.3 325.6 ± 19.6 <0.001 298.7 ± 1.2 305.8 ± 6.3 277.1 ± 17.5 300.2 ± 13.6 0.001 168.5 ± 1.8 160.3 ± 9.6 106.9 ± 14.3 145.8 ± 16.6 0.033


























Gender <0.001 0.138 <0.001
Male 67.2 54.4 54.3 56.5 46.5 46.3 40.9 53.0 57.5 42.6 48.4 48.5
Female 32.8 45.6 45.7 43.5 53.5 53.7 59.1 47.0 42.5 57.4 51.6 51.5
Marital Status 0.283 <0.001 <0.001
Single 8.3 11.6 6.3 7.4 12.9 15.2 17.3 10.2 14.8 20.5 28.0 16.2




20.3 17.4 34.4 18.5 21.5 25.0 40.1 22.3 16.4 16.3 29.7 17.0
Age at diagnosis 69.7 ± 12.6 68.0 ± 14.5 65.3 ± 13.2 66.3 ± 16.8 0.001 63.6 ± 16.3 61.4 ± 16.8 65.5 ± 16.4 64.1 ± 16.1 0.034 58.9 ± 17.2 53.5 ± 18.2 60.3 ± 18.5 57.0 ± 19.3 <0.001
Anatomic Site <0.001 0.010 <0.001
Face/head/
neck
60.3 70.4 37.0 46.4 1.8 1.3 0.5 0 18.6 17.5 9.9 10.6












Table 1 Patients’ characteristics and clinicopathologic features (Continued)
Upper
Extremity
19.3 11.6 6.5 14.5 20.2 16.3 15.3 19.0 23.7 19.7 11.3 17.5
Lower
Extremity
4.4 6.0 45.7 23.2 75.6 81.0 83.7 79.8 17.5 26.6 43.8 33.6
Other 0.6 0.4 2.2 0 0.2 0.3 0.5 1.2 8.0 11.7 19.7 18.4
Thickness of
tumor (mm)




No 96.1 97.2 89.1 89.9 94.5 92.7 93.5 86.9 89.3 85.5 79.1 80.8
Yes 0.5 0 8.7 2.9 2.8 3.7 3.7 6.5 0.8 1.1 2.7 1.5
Unknown 3.4 2.8 2.2 7.2 2.7 3.7 2.8 6.5 9.9 13.4 18.3 17.7
Ulceration <0.001 0.025 <0.001
No 88.8 85.6 67.4 82.6 70.5 65.3 62.3 60.7 78.0 72.2 60.0 65.5
Yes 2.9 2.8 8.7 4.3 24.6 29.0 33.0 33.3 6.6 9.7 15.1 10.0




None 75.8 75.6 63.0 69.6 68.0 70.3 69.3 60.7 71.6 66.6 49.4 54.1
Regional 0.7 1.2 6.5 4.3 14.9 20.0 11.6 23.2 4.8 8.6 14.1 9.3
Distant 0.1 0 2.2 1.4 0.9 41.3 1.4 0 0.8 1.2 2.7 2.3
Unknown 23.4 23.2 28.3 24.6 16.2 8.3 17.7 16.1 22.8 23.6 33.9 34.3
Stage <0.001 0.005 <0.001
In situ - - - - - - - - - - - -
Localized 93.5 93.2 73.9 85.5 67.7 60.7 66.5 53.0 77.3 66.3 44.7 57.7
Regional 3.2 3.2 17.4 8.7 27.2 31.3 26.5 39.9 8.8 14.6 21.1 15.3
Distant 0.3 0.4 4.3 1.4 3.3 4.3 4.7 5.4 6.3 10.3 20.6 16.4
Unstaged 2.9 3.2 4.3 4.3 1.8 3.7 2.3 1.8 7.7 8.8 13.7 10.6
Treatment 0.016 0.028 <0.001
No treatment 2.1 4.0 4.3 1.4 1.8 2.7 3.3 0.6 6.1 11.2 15.4 12.1
Surgery 96.2 94.8 93.5 92.8 96.8 94.3 94.4 94.6 88.7 82.5 73.0 78.0
Radiation 0.1 0 0 1.4 0.2 0.3 0 0.6 1.7 2.0 4.8 3.9
Radiation &
Surgery
0.9 0.4 0 2.9 1.3 2.3 2.3 3.6 2.5 3.6 4.1 4.4
Unknown 0.6 0.8 2.2 1.4 0 0.3 0 0.6 1.1 0.7 2.8 1.5
Survival
time (month)
181.9 ± 2.0 188.7 ± 14.2 153.0 ± 21.9 237.3 ± 25.1 0.138 158.4 ± 4.0 154.4 ± 10.4 133.4 ± 9.9 130.1 ± 12.1 0.023 243.0 ± 0.9 237.9 ± 5.8 144.6 ± 8.9 215.3 ± 10.1 <0.001












therapy, radiation, chemotherapy, and others. SEER con-
tains information on surgery and radiation but no other
treatments. As a result, patients in the “no surgery or
radiation” category might receive other types of treat-
ment, but this information is not available. For the ana-
lysis of incidence, SEER 13 contains detailed race and
incidence information for cancers diagnosed between
1992 and 2011. For the analysis of survival, SEER 18
contains information for cancers diagnosed between
1973 and 2006 and followed up to 12/31/2011.
Statistical analysis
Data on the six subtypes were analyzed separately. In the
analysis of patients’ characteristics, Chi-squared tests and
ANOVA were used to compare across racial groups for
categorical and continuous variables respectively. Age-
adjusted incidence rates were computed using SEER*Stat
and the U.S. Census 2000 data for age-standardization.
Five-year survival rates were calculated using SEER*Stat
and an actuarial method. Treatment was analyzed using
multivariate logistic regression, adjusted for age at diag-
nosis, gender, marital status, anatomic site, thickness of
tumor, and ulceration. Survival was analyzed using
multivariate Cox regression, adjusted for age at diagno-
sis, gender, marital status, anatomic site, thickness of
tumor, ulceration, and treatment. Analysis not achiev-
able using SEER software was conducted using SAS 9.3.
Results
Patients’ clinicopathologic characteristics
Results are shown in Table 1. Data on 376,797 patients
are analyzed. For all variables of interest, significant ra-
cial differences are observed for multiple or all subtypes,
and the patterns vary across subtypes. Specifically, for
MIS, there are more male patients for NHW but more
females for other races (p-value < 0.001). For NS, there
are more male patients for NHW and HW but not the
other two races. For LMM, there are more male patients
across all races, although the percentages differ (p-value
< 0.001). Significant racial differences in marital status
are observed for all subtypes expect for LMM. Blacks
have consistently lower rates of being married. Age at
diagnosis significantly differs across races for all sub-
types. For MIS and LMM, Asians/PIs and Blacks have
the lowest age at diagnosis. For the other four subtypes,
HWs have the lowest. For all subtypes, there are signifi-
cant racial differences in anatomic site, and the patterns
differ across subtypes. For example for MIS, the most
prevalent are trunk (NHW, 30.9 %), face/head/neck
(HW, 28.6 %), lower extremity (Black, 44.1 %), and lower
extremity (Asian/PI, 29.0 %), respectively. For ALM,
lower extremity is the dominating category for all races,
although the percentages differ. For MIS, there is no ra-
cial difference in thickness of tumor. For NM and ALM,
Asians/PIs have the thickest tumors, whereas for the
other three subtypes, Blacks have the thickest. For the
five subtypes with satellite nodule definition, the dom-
inating majority of patients have no satellite nodule.
The percentages differ significantly across races except
for NOS. The distribution of skin ulceration differs sig-
nificantly across races for all subtypes except for MIS,
but the patterns differ across subtypes. For example,
for SMM, the percentages of “No Ulceration” are 86.7,
87.6, 83.5, and 87.4 % for the four races, whereas for
NOS, the corresponding percentages are 78.0, 72.2,
60.0, and 65.5 %, respectively. For MIS, almost all pa-
tients have no lymph node extension, and thus there is
no racial difference. For the other five subtypes, there
are significant racial differences in lymph node exten-
sion. For SMM, there are more HWs without lymph
node extension, whereas there are more NHWs for
NM. Except for MIS, significant racial differences are
observed in stage, with more NHWs having localized
tumors. The dominating majority of patients were
treated with surgery, with significant racial differences
except for MIS. For all subtypes except for LMM, there
are significant racial differences in survival time. The
racial groups that have the longest survival are HW for
MIS and SSM and NHW for NM, ALM, and NOS.
Incidence
Results are shown in Table 2. The sample sizes are
49,313 (MIS), 46,860 (SSM), 9,639 (NM), 9,912 (LMM),
1,506 (ALM), and 62,622 (NOS), respectively. For the six
subtypes, the overall incidence rates per 100,000 person-
years are 6.60, 6.18, 1.30, 1.37, 0.20, and 8.36, respect-
ively. For all subtypes except for ALM, NHWs have the
highest age-adjusted incidence rates, followed by HWs,
while Blacks have the lowest. In the stratified analysis by
age and gender, the same pattern holds. In addition, it is
observed that incidence increases with age. For most
cases, males have higher incidence, with exceptions in-
cluding HWs with MIS and SSM. For ALM overall,
HWs have the highest incidence rate (0.24), followed by
NHWs (0.21), while Asians/PIs have the lowest rate
(0.17). In the stratified analysis by age, NHWs have the
highest rate for the <40 years age group, while HWs
have the highest rates for the 40–64 and 65+ years
groups. When stratified by gender, HWs have the high-
est rates for both groups. The incidence of ALM also in-
creases with age. The incidence rates are similar for
male and female.
Treatment
The analysis is conducted on 90,183 (MIS), 85,813 (SSM),
19,779 (NM), 16,987 (LMM), 2,454 (ALM), and 122,314
(NOS) samples, and summary results are shown in Table 3.
Detailed logistic regression analysis results are available
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Table 2 Age-adjusted incidence rates per 100,000 person-years, stratified by age and gender
NHW HW Black Asian/PI Total
Melanoma in situ
All ages 9.19 (9.11–9.28) 1.26 (1.18–1.35) 0.16 (0.13–0.20) 0.34 (0.30–0.38) 6.60 (6.54–6.66)
<40 years 2.18 (2.12–2.24) 0.21 (0.18–0.24) 0.03 (0.02–0.05) 0.10 (0.08–0.13) 1.31 (1.27–1.34)
40–64 years 13.97 (13.78–14.16) 1.61 (1.47–1.76) 0.19 (0.14–0.26) 0.48 (0.40–0.57) 9.82 (9.69–9.94)
65+ years 29.35 (28.93–29.77) 5.14 (4.63–5.70) 0.67 (0.49–0.90) 1.07 (0.87–1.31) 22.72 (22.41–23.04)
Male 10.71 (10.58–10.85) 1.22 (1.09–1.35) 0.19 (0.14–0.26) 0.35 (0.29–0.42) 7.95 (7.85–8.05)
Female 8.33 (8.22–8.45) 1.37 (1.26–1.48) 0.15 (0.11–0.19) 0.34 (0.29–0.39) 5.77 (5.70–5.85)
Superficial spreading melanoma
All ages 9.05 (8.96–9.13) 1.12 (1.05–1.19) 0.15 (0.12–0.18) 0.31 (0.27–0.35) 6.18 (6.13–6.24)
<40 years 3.35 (3.27–3.42) 0.35 (0.32–0.39) 0.04 (0.02–0.06) 0.11 (0.08–0.14) 1.96 (1.92–2.00)
40–64 years 14.73 (14.54–14.93) 1.81 (1.66–1.97) 0.20 (0.15–0.27) 0.47 (0.39–0.56) 10.04 (9.91–10.17)
65+ years 21.09 (20.74–21.45) 2.91 (2.53–3.33) 0.51 (0.35–0.71) 0.81 (0.64–1.02 15.93 (15.67–16.20)
Male 10.23 (10.10–10.37) 0.98 (0.88–1.09) 0.18 (0.13–0.24) 0.34 (0.28–0.41) 7.20 (7.11–7.29)
Female 8.27 (8.16–8.39) 1.29 (1.19–1.39) 0.13 (0.09–0.17) 0.29 (0.24–0.34) 5.49 (5.42–5.57)
Nodular melanoma
All ages 1.80 (1.76–1.84) 0.49 (0.44–0.54) 0.06 (0.04–0.08) 0.14 (0.12–0.17) 1.30 (1.28–1.33)
<40 years 0.38 (0.35–0.40) 0.08 (0.06–0.10) 0.01 (0.00–0.02) 0.04 (0.02–0.06) 0.23 (0.21–0.24)
40–64 years 2.31 (2.24–2.39) 0.51 (0.43–0.60) 0.06 (0.03–0.10) 0.14 (0.10–0.19) 1.60 (1.55–1.65)
65+ years 6.98 (6.78–7.19) 2.26 (1.92–2.65) 0.31 (0.19–0.48) 0.63 (0.47–0.82) 5.46 (5.30–5.61)
Male 2.51 (2.45–2.58) 0.60 (0.51–0.70) 0.07 (0.04–0.12) 0.19 (0.14–0.24) 1.84 (1.80–1.89)
Female 1.26 (1.22–1.30) 0.42 (0.36–0.48) 0.05 (0.03–0.08) 0.11 (0.08–0.15) 0.91 (0.88–0.93)
Lentigo maligna melanoma
All ages 1.87 (1.83–1.90) 0.23 (0.19–0.27) 0.02 (0.01–0.04) 0.06 (0.05–0.08) 1.37 (1.35–1.40)
<40 years 0.05 (0.04–0.06) 0.01 (0.00–0.01) 0.00 0.01 (0.00–0.02) 0.03 (0.03–0.04)
40–64 years 1.83 (1.77–1.90) 0.17 (0.13–0.23) 0.01 (0.00–0.04) 0.05 (0.03–0.09) 1.26 (1.22–1.31)
65+ years 10.11 (9.87–10.36) 1.38 (1.11–1.69) 0.16 (0.08–0.29) 0.33 (0.22–0.47) 7.69 (7.51–7.87)
Male 2.97 (2.90–3.04) 0.33 (0.26–0.41) 0.04 (0.02–0.08) 0.09 (0.06–0.13) 2.21 (2.16–2.26)
Female 1.05 (1.02–1.09) 0.17 (0.13–0.21) 0.01 (0.00–0.03) 0.04 (0.02–0.06) 0.77 (0.74–0.80)
Acral lentiginous melanoma, malignant
All ages 0.21 (0.20–0.22) 0.24 (0.21–0.28) 0.19 (0.16–0.23) 0.17 (0.14–0.20) 0.20 (0.19–0.22)
<40 years 0.04 (0.03–0.05) 0.02 (0.01–0.02) 0.02 (0.01–0.03) 0.02 (0.01–0.03) 0.03 (0.03–0.04)
40–64 years 0.25 (0.23–0.28) 0.26 (0.20–0.32) 0.21 (0.16–0.28) 0.17 (0.13–0.23) 0.24 (0.22–0.26)
65+ years 0.87 (0.80–0.95) 1.24 (0.99–1.54) 0.93 (0.71–1.20) 0.85 (0.67–1.07) 0.90 (0.84–0.96)
Male 0.22 (0.20–0.24) 0.25 (0.19–0.31) 0.22 (0.16–0.30) 0.20 (0.16–0.26) 0.22 (0.20–0.23)
Female 0.21 (0.19–0.23) 0.24 (0.20–0.30) 0.18 (0.14–0.22) 0.14 (0.11–0.18) 0.20 (0.18–0.21)
Malignant melanoma, NOS
All ages 11.73 (11.64–11.83) 2.25 (2.14–2.36) 0.51 (0.45–0.57) 0.66 (0.60–0.72) 8.36 (8.29–8.42)
<40 years 3.37 (3.30–3.44) 0.48 (0.44–0.53) 0.10 (0.07–0.13) 0.17 (0.14–0.21) 2.02 (1.98–2.07)
40–64 years 17.35 (17.14–17.56) 2.98 (2.78–3.18) 0.57 (0.48–0.67) 0.83 (0.72–0.94) 12.10 (11.96–12.24)
65+ years 35.91 (35.45–36.38) 8.46 (7.79–9.18) 2.22 (1.87–2.62) 2.42 (2.11–2.77) 27.92 (27.58–28.28)
Male 14.63 (14.47–14.79) 2.31 (2.13–2.49) 0.63 (0.53–0.75) 0.69 (0.61–0.79) 10.68 (10.57–10.80)
Female 9.70 (9.58–9.82) 2.30 (2.16–2.44) 0.43 (0.36–0.50) 0.64 (0.57–0.72) 6.74 (6.66–6.82)
Diagnosed in the period of 1992–2011 in the SEER 13 database. In each cell, estimate (95 % CI). Rates are age-standardized using the U.S. 2000 Census population
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Table 3 Treatment strategy, stratified by stage-at-diagnosis
NHW HW Black Asian/PI P-value
Melanoma in situ
In situ No treatment 3641 (4.2) 109 (5.8) 11 (5.0) 17 (4.2) 0.142
Surgery 83560 (95.3) 1770 (93.8) 210 (95.0) 385 (95.5)
Radiation 117 (0.1) 2 (0.1) 0 1 (0.2)
Radiation & Surgery 354 (0.4) 6 (0.3) 0 0
Superficial spreading melanoma
Localized No treatment 1106 (1.4) 38 (2.1) 3 (1.6) 8 (2.5) 0.877
Surgery 76782 (98.0) 1764 (97.5) 183 (97.9) 306 (95.6)
Radiation 16 (0.0) 0 0 0
Radiation & Surgery 440 (0.6) 7 (0.4) 1 (0.5) 6 (1.9)
Regional No treatment 19 (0.4) 0 0 0 0.999
Surgery 4366 (95.4) 142 (96.6) 20 (95.2) 34 (97.1)
Radiation 4 (0.1) 0 0 0
Radiation & Surgery 188 (4.1) 5 (3.4) 1 (4.8) 1 (2.9)
Distant No treatment 15 (4.2) 0 0 0 0.650
Surgery 259 (73.4) 12 (80.0) 1 (50.0) 3 (100.0)
Radiation 9 (2.5) 0 0 0
Radiation & Surgery 70 (19.8) 3 (20.0) 1 (50.0) 0
Nodular melanoma
Localized No treatment 149 (1.3) 5 (1.4) 2 (4.5) 1 (1.2) 0.585
Surgery 11613 (97.5) 344 (98.0) 42 (95.5) 81 (97.6)
Radiation 12 (0.1) 0 0 1 (1.2)
Radiation & Surgery 137 (1.2) 2 (0.6) 0 0
Regional No treatment 41 (0.7) 2 (0.7) 0 0 0.571
Surgery 5792 (94.2) 259 (93.8) 39 (95.1) 63 (95.5)
Radiation 2 (0.0) 0 0 1 (1.5)
Radiation & Surgery 312 (5.1) 15 (5.4) 2 (4.9) 2 (3.0)
Distant No treatment 42 (5.3) 4 (8.2) 0 0 0.346
Surgery 553 (70.3) 40 (81.6) 11 (73.3) 6 (66.7)
Radiation 9 (1.1) 0 0 0
Radiation & Surgery 183 (23.3) 5 (10.2) 4 (26.7) 3 (33.3)
Lentigo maligna melanoma
Localized No treatment 301 (1.9) 7 (3.0) 1 (2.9) 0 0.986
Surgery 15617 (97.4) 224 (96.6) 33 (97.1) 56 (96.6)
Radiation 5 (0.0) 0 0 1 (1.7)
Radiation & Surgery 104 (0.6) 1 (0.4) 0 1 (1.7)
Regional No treatment 4 (0.7) 0 1 (12.5) 0 0.759
Surgery 513 (92.9) 8 (100.0) 7 (87.5) 5 (83.3)
Radiation - - - -
Radiation & Surgery 35 (6.3) 0 0 1 (16.7)
Distant No treatment 2 (3.4) 0 0 0 0.992
Surgery 40 (69.0) 1 (100.0) 2 (100.0) 1 (100.0)
Radiation 2 (3.4) 0 0 0
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from the authors. For the first five subtypes and lo-
calized and regional NOS, the dominating majority of
patients had surgery. For distant NOS, the distribu-
tion of treatment is: 38.0 % no surgery or radiation,
27.6 % surgery, 15.2 % radiation, and 19.1 % both ra-
diation and surgery. In the multivariate logistic re-
gression, there are no significant racial differences for
the first four subtypes and localized and regional
ALM. For the distant stage of ALM, the multivariate
logistic regression generates a significant p-value
(0.022). It is noted that this significance should be
interpreted with cautions because of the small counts.
For localized and regional NOS, significant differences
are observed across races. For localized, NHWs had
the highest rate of surgery (97.4 %), while Blacks had
the lowest (94.6 %). For regional, Blacks had the high-
est rate of surgery (92.2 %), while HWs had the low-
est (81.7 %). For distant, there are many more
patients in the “no surgery or radiation treatment”
category, and there is significant difference across
races (p-value < 0.001).
Survival
The analysis is based on 70,898 (MIS), 74,490 (SSM),
16,286 (NM), 12,507 (LMM), 2,047 (ALM), and
100,865 (NOS) samples. The summary results are
shown in Table 4. Detailed multivariate Cox regression
analysis results are shown in Table 5 in Appendix. The
survival curves for up to five years are shown in Fig. 1
(all stages combined) and Fig. 2 (stratified by stage at
diagnosis). Note that for MIS, the five-year survival
rates are 100 % and thus not plotted. For SSM, the ra-
cial groups with the best five-year survival are Black
(localized, 100 %), HW (regional, 74.1 %), and HW
(distant, 46.8 %). For NS, the racial groups with the
best survival are NHW (localized, 80.6 %), Asian/PI
Table 3 Treatment strategy, stratified by stage-at-diagnosis (Continued)
Radiation & Surgery 14 (24.1) 0 0 0
Acral lentiginous melanoma, malignant
Localized No treatment 23 (1.9) 3 (1.6) 5 (3.5) 1 (1.1) 0.841
Surgery 1201 (97.3) 178 (97.8) 138 (96.5) 87 (97.8)
Radiation 2 (0.2) 0 0 0
Radiation & Surgery 8 (0.6) 1 (0.5) 1 (0.5) 1 (1.1)
Regional No treatment 3 (0.6) 0 1 (1.8) 0 0.301
Surgery 481 (97.2) 89 (94.7) 54 (94.7) 65 (97.0)
Radiation - - - -
Radiation & Surgery 11 (2.2) 5 (5.3) 2 (3.5) 2 (3.0)
Distant No treatment 1 (1.6) 1 (7.7) 0 0 0.022
Surgery 54 (88.5) 11 (84.6) 7 (70.0) 5 (55.6)
Radiation 1 (1.6) 1 (7.7) 0 1 (11.1)
Radiation & Surgery 5 (8.2) 0 3 (33.3) 3 (30.0)
Malignant melanoma, NOS
Localized No treatment 1950 (2.0) 84 (3.3) 14 (4.0) 18 (3.6) <0.001
Surgery 95929 (97.4) 2425 (96.2) 330 (94.6) 475 (95.6)
Radiation 70 (0.1) 0 2 (0.6) 0
Radiation & Surgery 591 (0.6) 13 (0.5) 3 (0.9) 4 (0.8)
Regional No treatment 882 (7.9) 52 (9.4) 2 (1.2) 7 (5.3) 0.010
Surgery 9397 (84.3) 451 (81.7) 153 (92.2) 116 (87.9)
Radiation 69 (0.6) 7 (1.3) 1 (0.6) 1 (0.8)
Radiation & Surgery 801 (7.2) 42 (7.6) 10 (6.0) 8 (6.1)
Distant No treatment 2901 (37.5) 175 (44.9) 71 (46.1) 50 (37.6) <0.001
Surgery 2136 (27.6) 97 (24.9) 51 (33.1) 40 (30.1)
Radiation 1192 (15.4) 48 (12.3) 17 (11.0) 25 (18.8)
Radiation & Surgery 1501 (19.4) 70 (17.9) 15 (9.7) 18 (13.5)
Cancers diagnosed in the period of 1973–2011 in the SEER 18 database. In each cell, count (percentage). P-values were obtained from multivariate
logistic regression
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(regional, 62.9 %), and HW (distant, 34.4 %). For
LMM, the groups with the best survival are Black and
NHW (localized, 100 %), NHW (regional, 75.6 %), and
Black (distant, 69.4 %). For ALM, the groups with the
best survival are NHW (localized, 97.5 %), Asian/PI
(regional, 62.1 %), and Black (distant, 28.7 %). For
NOS, NHWs have the best survival with localized
(97.2 %) and regional (61.4 %) tumors, and HWs have
the best survival with distant tumors (17.0 %). For the
first five subtypes, racial differences are not significant
in the Cox regression after accounting for confounders.
For NOS, significant racial differences are observed for
the localized and regional stages. Figures 1 and 2 pro-
vide more detailed information on the survival rates be-
tween time zero and year five. Figure 2 shows that the
localized stage has the best relative survival rates for all
five subtypes. In contrast, the distant stage has the
worst survival rates. The separation of survival curves
is the most distinct for SMM with the localized stage,
LMM with the localized and distant stages, and NOS
with the distant stage, while there are some crossovers
for the other subtypes.
Discussion
Main findings
The epidemiology of melanoma overall and its subtypes
has been studied in a large number of publications. It
has been noted that race causes differences in multiple
aspects. However, most of the existing studies only in-
clude race as a confounding variable and have not paid
sufficient attention. This study advances from the exist-
ing ones by comprehensively analyzing the six most
major subtypes on the same ground for four largest ra-
cial groups. For the U.S. and other countries that have a
significant race mixture, observations made in this study
can provide valuable insights for public health and clin-
ical investigators.
Melanoma is a rare disease in minorities. For all sub-
types, there are dominatingly more NHW patients. The
counts for the other races are relatively small for some
subtypes. This can be especially problematic in the
stratified analysis, and thus some results should be inter-
preted cautiously. For all of the patients’ characteristic
variables examined in Table 1, significant racial differ-
ences are observed for at least some, if not all, subtypes,
Table 4 Five-year relative survival rates, stratified by stage-at-diagnosis
Total NHW HW Black Asian/PI P-value
Melanoma in situ
In situ 100.0 100.0 100.0 100.0 100.0 0.380
Superficial spreading melanoma
Localized 99.2 (98.9–99.4) 99.0 (98.7–99.2) 98.2 (96.1–99.2) 100.0 94.0 (87.7–97.1) 0.844
Regional 71.5 (69.7–73.2) 71.4 (69.6–73.2) 74.1 (62.9–82.4) 67.5 (33.5–86.8) 60.7 (40.0–76.3) 0.623
Distant 33.8 (27.7–40.0) 33.0 (26.7–39.5) 46.8 (18.1–71.4) 0.0 33.7 (0.9–77.9) 0.987
Nodular melanoma
Localized 80.6 (79.5–81.7) 80.6 (79.4–81.7) 79.7 (72.4–85.4) 63.9 (39.0–80.8) 72.9 (56.8–83.8) 0.403
Regional 55.1 (53.4–56.7) 55.3 (53.6–57.0) 47.6 (39.5–55.1) 46.5 (24.7–65.7) 62.9 (46.9–75.3) 0.119
Distant 17.1 (13.9–20.6) 16.2 (12.9–19.7) 34.4 (17.6–51.9) 27.1 (4.9–56.8) 13.3 (0.7–44.3) 0.101
Lentigo maligna melanoma
Localized 100.0 100.0 97.3 (61.0–99.8) 100.0 96.1 (53.3–99.8) 0.697
Regional 73.2 (65.6–79.4) 75.6 (67.7–81.8) 58.1 (3.7–91.5) 19.1 (0.8–56.9) 31.7 (0.7–76.9) 0.151
Distant 26.1 (11.3–43.8) 24.2 (9.5–42.4) 0.0 69.4 (0.0–99.2) 0.0 0.508
Acral lentiginous melanoma, malignant
Localized 96.0 (92.6–97.8) 97.5 (92.4–99.2) 95.0 (75.3–99.1) 91.9 (74.9–97.6) 87.4 (70.7–94.9) 0.266
Regional 58.4 (52.9–63.5) 60.3 (53.5–66.5) 50.6 (37.0–62.7) 49.8 (29.3–67.3) 62.1 (44.5–75.5) 0.447
Distant 15.8 (7.7–26.5) 13.8 (4.8–27.5) 12.0 (0.7–40.7) 28.7 (4.9–59.7) 20.3 (0.8–58.8) 0.651
Malignant melanoma, NOS
Localized 97.3 (97.1–97.6) 97.2 (96.9–97.5) 95.6 (93.7–96.9) 86.0 (78.2–91.1) 93.1 (88.6–95.9) 0.013
Regional 61.1 (59.8–62.2) 61.4 (60.2–62.7) 57.0 (51.4–62.2) 48.1 (37.7–57.7) 53.8 (42.8–63.6) 0.007
Distant 14.3 (13.4–15.3) 14.1 (13.1–15.1) 17.0 (12.5–22.1) 16.4 (9.7–24.6) 9.6 (4.6–16.7) 0.501
Cancers diagnosed in the period of 1973–2006 and followed up to 12/31/2011 in the SEER 18 database. In each cell, estimated rate (95 % CI). P-values were
obtained from multivariate Cox regression
Wang et al. BMC Cancer  (2016) 16:691 Page 10 of 19
Table 5 Multivariate Cox regression analysis of survival, stratified by stage at diagnosis
In situ Localized Regional Distant
HR 95 % CI P HR 95 % CI P HR 95 % CI P HR 95 % CI P
Melanoma in situ
Gender - - - - - - - - -
Male 1 - - - - - - - - -
Female 0.502 0.398–0.634 0.000 - - - - - - - - -
Age at diagnosis 1.098 1.087–1.110 0.000 - - - - - - - - -
Marital Status - - - - - - - - -
Single 1 - - - - - - - - -
Married 0.770 0.539–1.099 0.150 - - - - - - - - -
Separated/divorced/widowed 1.225 0.831–1.806 0.305 - - - - - - - - -
Ethnic group - - - - - - - - -
NHW 1 - - - - - - - - -
HW 1.886 0.888–4.006 0.099 - - - - - - - - -
Black 0.709 0.098–5.115 0.733 - - - - - - - - -
Asian/PI 0.624 0.087–4.495 0.640 - - - - - - - - -
Anatomic Site - - - - - - - - -
Face/head/neck 1 - - - - - - - - -
Trunk 0.993 0.783–1.259 0.952 - - - - - - - - -
Upper Extremity 0.876 0.668–1.149 0.338 - - - - - - - - -
Lower Extremity 0.753 0.500–1.133 0.174 - - - - - - - - -
Other 1.081 0.399–2.929 0.878 - - - - - - - - -
Treatment - - - - - - - - -
No surgery or radiation 1 - - - - - - - - -
Surgery 1.125 0.531–2.387 0.758 - - - - - - - - -
Radiation 0.185 – 0.989 - - - - - - - - -
Radiation & Surgery 1.041 0.214–5.063 0.961 - - - - - - - - -
Thickness of tumor (mm) 1.043 0.993–1.095 0.091 - - - - - - - - -
Ulceration - - - - - - - - -
No 1 - - - - - - - - -
Yes 1.722 0.847–3.503 0.133 - - - - - - - - -
Superficial spreading melanoma
Gender
Male - - - 1 1 1
Female - - - 0.709 0.677–0.742 0.000 0.718 0.644–0.801 0.000 0.657 0.452–0.955 0.028
Age at diagnosis - - - 1.074 1.072–1.075 0.000 1.033 1.029–1.036 0.000 1.018 1.007–1.029 0.001
Marital Status
Single - - - 1 1 1
Married - - - 0.741 0.693–0.792 0.000 0.724 0.631–0.832 0.000 0.505 0.337–0.757 0.001
Separated/divorced/widowed - - - 1.034 0.957–1.117 0.400 0.897 0.759–1.059 0.199 0.791 0.480–1.301 0.355
Ethnic group
NHW - - - 1 1 1
HW - - - 1.065 0.915–1.241 0.416 1.213 0.909–1.620 0.190 0.931 0.468–1.850 0.837
Black - - - 0.920 0.605–1.398 0.696 0.954 0.549–1.657 0.867 1.171 0.156–8.812 0.878
Asian/PI - - - 1.008 0.726–1.398 0.964 1.028 0.606–1.745 0.918 0.821 0.196–3.447 0.788
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Table 5 Multivariate Cox regression analysis of survival, stratified by stage at diagnosis (Continued)
Anatomic Site
Face/head/neck - - - 1 1 1
Trunk - - - 0.849 0.804–0.896 0.000 0.896 0.788–1.020 0.098 1.570 1.062–2.319 0.024
Upper Extremity - - - 0.750 0.707–0.795 0.000 0.800 0.692–0.925 0.003 1.606 1.034–2.493 0.035
Lower Extremity - - - 0.655 0.611–0.701 0.000 0.820 0.707–0.951 0.009 1.384 0.825–2.323 0.218
Other - - - 1.031 0.731–1.455 0.860 1.359 0.507–3.646 0.542 0.000 – 0.954
Treatment
No surgery or radiation - - - 1 1 1
Surgery - - - 0.584 0.468–0.729 0.000 2.030 0.652–6.316 0.222 0.274 0.116–0.645 0.003
Radiation - - - 1.738 0.427–7.077 0.440 5.760 0.597–55.57 0.130 1.454 0.397–5.328 0.572
Radiation & Surgery - - - 1.175 0.841–1.640 0.345 4.154 1.316–13.11 0.015 0.750 0.306–1.836 0.529
Thickness of tumor (mm) - - - 1.223 1.207–1.239 0.000 1.152 1.128–1.176 0.000 1.107 1.043–1.175 0.001
Ulceration
No - - - 1 1 1
Yes - - - 1.355 1.226–1.498 0.000 1.082 0.984–1.190 0.102 1.011 0.703–1.453 0.954
Nodular melanoma
Gender
Male - - - 1 1 1
Female - - - 0.753 0.698–0.812 0.000 0.790 0.728–0.858 0.000 1.069 0.879–1.299 0.504
Age at diagnosis - - - 1.048 1.045–1.050 0.000 1.028 1.026–1.031 0.000 1.010 1.004–1.015 0.001
Marital Status
Single - - - 1 1 1
Married - - - 0.707 0.636–0.785 0.000 0.799 0.722–0.885 0.000 0.763 0.600–0.970 0.027
Separated/divorced/widowed - - - 0.944 0.838–1.063 0.341 1.001 0.887–1.129 0.987 0.880 0.663–1.167 0.374
Ethnic group
NHW - - - 1 1 1
HW - - - 0.924 0.739–1.155 0.486 1.150 0.958–1.380 0.134 0.625 0.416–0.940 0.024
Black - - - 1.533 0.887–2.647 0.126 1.335 0.876–2.035 0.179 0.597 0.243–1.467 0.261
Asian/PI - - - 0.938 0.597–1.475 0.783 0.781 0.540–1.128 0.187 0.959 0.469–1.961 0.910
Anatomic Site
Face/head/neck - - - 1 1 1
Trunk - - - 1.046 0.957–1.143 0.320 1.125 1.023–1.238 0.016 1.284 1.027–1.605 0.029
Upper Extremity - - - 0.846 0.773–0.926 0.000 0.901 0.813–0.998 0.046 0.960 0.745–1.237 0.750
Lower Extremity - - - 0.832 0.743–0.931 0.001 0.984 0.879–1.101 0.775 0.936 0.711–1.232 0.636
Other - - - 0.974 0.572–1.660 0.923 0.940 0.518–1.705 0.838 3.880 0.942–15.986 0.061
Treatment
No surgery or radiation - - - 1 1 1
Surgery - - - 0.498 0.358–0.692 0.000 0.416 0.276–0.628 0.000 0.459 0.282–0.748 0.002
Radiation - - - 1.813 0.644–5.102 0.260 0.418 0.056–3.102 0.394 0.626 0.210–1.866 0.400
Radiation & Surgery - - - 1.012 0.667–1.536 1.012 0.648 0.419–1.003 0.051 0.678 0.409–1.124 0.132
Thickness of tumor (mm) - - - 1.120 1.104–1.136 0.000 1.074 1.060–1.088 0.000 1.017 0.989–1.044 0.235
Ulceration
No - - - 1 1 1
Yes - - - 1.215 1.116–1.323 0.000 1.074 1.000–1.155 0.051 0.834 0.699–0.997 0.046
Lentigo maligna melanoma
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Table 5 Multivariate Cox regression analysis of survival, stratified by stage at diagnosis (Continued)
Gender
Male - - - 1 1 1
Female - - - 0.641 0.589–0.698 0.000 0.641 0.471–0.872 0.005 1.968 0.468–8.271 0.355
Age at diagnosis - - - 1.093 1.088–1.097 0.000 1.050 1.036–1.065 0.000 1.016 0.965–1.070 0.550
Marital Status
Single - - - 1 1 1
Married - - - 0.758 0.660–0.870 0.000 0.858 0.508–1.449 0.566 1.701 0.345–8.396 0.514
Separated/divorced/widowed - - - 0.939 0.808–1.091 0.409 1.137 0.657–1.969 0.646 0.744 0.082–6.771 0.793
Ethnic group
NHW - - - 1 1 1
HW - - - 0.981 0.723–1.330 0.900 0.619 0.196–1.954 0.414 - - -
Black - - - 1.029 0.486–2.180 0.940 9.996 1.239–80.642 0.031 0.308 0.009–10.073 0.508
Asian - - - 0.587 0.244–1.412 0.234 1.120 0.331–3.793 0.855 - - -
Anatomic Site
Face/head/neck - - - 1 1 1
Trunk - - - 0.909 0.812–1.018 0.099 1.068 0.666–1.713 0.785 5.787 1.173-28.562 0.031
Upper Extremity - - - 0.888 0.806–0.978 0.016 0.988 0.656–1.488 0.954 1.564 0.145–16.844 0.712
Lower Extremity - - - 0.802 0.655–0.981 0.032 0.670 0.363–1.234 0.198 - - -
Other - - - 1.218 0.792–1.873 0.369 - - - - - -
Treatment
No surgery or radiation - - - 1 1 - - -
Surgery - - - 0.734 0.530–1.015 0.062 1.768 0.245–12.759 0.572 1
Radiation - - - 0.017 – 0.902 - - - 135.011 – 0.000
Radiation & Surgery - - - 1.202 0.703–2.056 0.501 3.478 0.445–27.195 0.235 7.513 1.689–33.427 0.008
Thickness of tumor (mm) - - - 1.130 1.098–1.162 0.000 1.094 1.030–1.161 0.003 1.142 0.893–1.460 0.289
Ulceration
No - - - 1 1 1
Yes - - - 1.243 0.971–1.592 0.085 1.242 0.949–1.626 0.114 2.834 0.458–17.545 0.263
Acral lentiginous melanoma, malignant
Gender
Male - - - 1 1 1
Female - - - 0.810 0.649–1.011 0.062 0.595 0.471–0.752 0.000 0.828 0.449–1.529 0.546
Age at diagnosis - - - 1.069 1.059–1.079 0.000 1.025 1.017–1.034 0.000 1.040 1.013–1.067 0.003
Marital Status
Single - - - 1 1 1
Married - - - 0.922 0.638–1.332 0.665 0.790 0.550–1.136 0.204 0.340 0.120–0.967 0.043
Separated/divorced/widowed - - - 1.063 0.719–1.572 0.761 1.093 0.744–1.606 0.652 0.337 0.099–1.147 0.082
Ethnic group
Non-Hispanic white - - - 1 1 1
Hispanic white - - - 0.771 0.530–1.123 0.176 1.219 0.884–1.682 0.228 0.987 0.409–2.381 0.977
Black - - - 1.112 0.803–1.540 0.523 1.080 0.751–1.553 0.678 0.601 0.254–1.420 0.246
Asian - - - 1.307 0.826–2.068 0.254 0.843 0.568–1.250 0.396 0.630 0.183–2.176 0.465
Anatomic Site
Face/head/neck - - - 1 1 - - -
Trunk - - - 0.845 0.280–2.552 0.765 0.770 0.123–4.845 0.781 1
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Table 5 Multivariate Cox regression analysis of survival, stratified by stage at diagnosis (Continued)
Upper Extremity - - - 0.978 0.447–2.140 0.956 0.933 0.275–3.162 0.912 0.253 0.045–1.403 0.116
Lower Extremity - - - 1.004 0.472–2.139 0.991 1.277 0.383–4.250 0.691 0.302 0.060–1.509 0.145
Other - - - 0.913 0.111–7.533 0.933 0.011 – 0.962 - - -
Treatment
No surgery or radiation - - - 1 1 1
Surgery - - - 0.372 0.162–0.855 0.020 0.065 0.020–0.213 0.000 0.150 0.031–0.718 0.018
Radiation - - - 0.431 0.049–3.766 0.446 - - - 0.946 0.112–7.994 0.959
Radiation & Surgery - - - 0.151 0.018–1.271 0.082 0.179 0.047–0.687 0.012 0.528 0.091–3.061 0.476
Thickness of tumor (mm) - - - 1.137 1.072–1.206 0.000 1.115 1.069–1.163 0.000 1.094 0.988–1.211 0.083
Ulceration
No - - - 1 1 1
Yes - - - 1.544 1.112–2.143 0.009 1.103 0.888–1.368 0.376 2.281 1.216–4.280 0.010
Malignant melanoma, NOS
Gender
Male - - - 1 1 1
Female - - - 0.705 0.676–0.735 0.000 0.800 0.742–0.862 0.000 0.881 0.752–1.032 0.117
Age at diagnosis - - - 1.069 1.068–1.071 0.000 1.033 1.031–1.035 0.000 1.014 1.010–1.019 0.000
Marital Status
Single - - - 1 1 1
Married - - - 0.731 0.690–0.776 0.000 0.777 0.704–0.857 0.000 0.630 0.521–0.762 0.000
Separated/divorced/widowed - - - 0.985 0.921–1.054 0.660 0.993 0.886–1.114 0.910 0.848 0.673–1.069 0.163
Ethnic group
NHW - - - 1 1 1
HW - - - 1.134 1.002–1.284 0.046 1.240 1.056–1.455 0.009 0.970 0.704–1.336 0.852
Black - - - 1.389 1.086–1.777 0.009 1.372 1.056–1.782 0.018 0.859 0.516–1.431 0.561
Asian/PI - - - 1.004 0.782–1.290 0.973 1.052 0.772–1.434 0.748 1.478 0.850–2.571 0.167
Anatomic Site
Face/head/neck - - - 1 1 1
Trunk - - - 0.918 0.876–0.962 0.000 1.087 0.994–1.189 0.068 1.098 0.913–1.320 0.320
Upper Extremity - - - 0.811 0.772–0.852 0.000 0.859 0.779–0.948 0.003 0.970 0.782–1.203 0.778
Lower Extremity - - - 0.732 0.687–0.779 0.000 0.910 0.823–1.006 0.065 0.835 0.672–1.037 0.103
Other - - - 0.911 0.690–1.201 0.506 1.416 0.908–2.208 0.125 1.011 0.631–1.619 0.964
Treatment
No surgery or radiation - - - 1 1 1
Surgery - - - 0.656 0.572–0.752 0.000 0.392 0.291–0.530 0.000 0.472 0.357–0.626 0.000
Radiation - - - 2.551 1.424–4.570 0.002 1.886 0.886–4.016 0.100 1.647 1.033–2.625 0.036
Radiation & Surgery - - - 1.312 1.069–1.610 0.009 0.732 0.531–1.011 0.058 0.747 0.549–1.016 0.063
Thickness of tumor (mm) - - - 1.196 1.183–1.208 0.000 1.086 1.073–1.099 0.000 1.045 1.021–1.069 0.000
Ulceration
No - - - 1 1 1
Yes - - - 1.448 1.351–1.553 0.000 1.172 1.097–1.252 0.000 1.002 0.858–1.172 0.975
Cancers diagnosed 1973–2006 and followed up to 12/31/2011
HR hazard ratio
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Fig. 1 Relative survival rates up to five years, for all stages combined. Cancers diagnosed in the period of 1973–2006 and followed up to 12/31/2011
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Fig. 2 Relative survival rates up to five years, stratified by stage. Cancers diagnosed in the period of 1973–2006 and followed up to 12/31/2011
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and the patterns vary across subtypes. The development
of melanoma is extremely complicated. The heterogen-
eity in etiology and presentation among subtypes have
been previously noted [14]. The observed differences
across races and across subtypes reflect the complex in-
teractions of occupational exposures (especially to UV
light,) environment (closer to the equator or at a higher
elevation), genetic makeup (which, for example, causes
difference in skin and hair color), family history, defi-
ciency in the immune system, and socioeconomic status.
Some of the observed across-subtype differences, for
example in gender and marital status, can be con-
founded with other factors such as socioeconomic sta-
tus. In the literature [6, 15, 16], it has been suggested
that minorities, especially Blacks and Hispanics, are
more likely to be diagnosed at later stages and have ad-
vanced presentations. In our analysis, Blacks have stages
later than the other races for all subtypes except for
ALM. It has been suggested that this can be a conse-
quence of economic, social, and cultural barriers such as
low income, lack of insurance, lower levels of education,
lower levels of melanoma awareness and knowledge, and
lower rates of participation in melanoma screening [15,
17]. However in the literature, subtype-specific analysis
of socioeconomic status is still lacking.
The incidence of melanoma is extremely complex. The
most prominent risk factor is exposure to UV light. A
large number of potential risk factors have been sug-
gested, including presence of fair skin, freckling and light
hair, family history, personal history of melanoma and
other skin cancers, older age, male gender, and xero-
derma pigmentosum (XP) [18]. In addition, a large num-
ber of genetic risk factors have been suggested, including
germline mutations such as CDKN2A (which leads to
destabilization of p53), CDK4, BAP1, MC1R, and MITF,
and somatic mutations for example in the RAS-RAF-
MEK-MAPK and PI3K-PTEN-AKT pathways [19]. For
five out of six subtypes, the overall incidence rate pat-
terns are relatively consistent across races. It has been
long noted that NHWs have a higher incidence rate.
This can be attributable to certain physical characteris-
tics (for example light skin and hair color), lifestyle fac-
tors (for example more exposure to UV light), genetic
risk factors, as well as others [20]. The analysis also sug-
gests that there exists interaction between gender and
race – it is observed that females have higher incidence
among HWs for MIS and SSM, but for other cases, the
trend is reversed. Previous studies have noted the inter-
action between gender and age for incidence [21]. How-
ever the interaction observed in this study has been less
acknowledged. Some of the genetic risk factors may also
interact with race. For example, all red-haired people
have a mutated copy of MC1R. Overall, research on the
distribution of genetic risk factors across races has been
rare. The observation for ALM is different from the
other subtypes. ALM is the most common type of mel-
anoma in the Asian, Hispanic, and African populations.
The fundamental difference of this subtype has been ex-
amined in the literature [22] and is not reiterated here.
The primary treatment for melanoma is surgical exci-
sion. Systemic adjuvant therapies (levamisole, interferon,
vaccines, and chemotherapy) and radiotherapy may be
considered for patients with high risk melanomas, in-
cluding those with lymph node involvement and distant
metastases. For most of the subtypes/stages, racial differ-
ences, although observed, are not statistically significant
after adjusting for confounders. The difference observed
for the distant stage of ALM should be taken with cau-
tions because of the small sample size. For the localized
stage of NOS, as most patients (at least 94.6 %) had sur-
gery, the observed racial difference may not be clinically
meaningful. For regional and distant tumors, the racial
differences are more prominent. For regional tumors,
Blacks had the highest rate of surgery (92.2 %), while
HWs had the lowest (81.7 %). For distant tumors, all
racial groups had more “scattered” treatment distribu-
tions. For a variety of solid tumors, racial differences in
treatment have been well documented [23–25]. In par-
ticular, Blacks have been shown to be given less than op-
timal care [26, 27]. However, our analysis suggests that
there is no such racial difference for melanoma treat-
ment. A similar observation has been made for Blacks
and Whites [28]. Treatment selection is a complex
process involving multiple factors. The differences in
patients’ characteristics, as previously observed, contrib-
ute to at least some of the differences. In addition, it has
been suggested in the literature that socioeconomic sta-
tus, insurance status, disparity (that is independent of
socioeconomic status), cultural and behavioral differ-
ences all contribute to treatment selection [29]. It is
noted that such information is not available from SEER.
Analysis suggests certain racial differences in the
five-year survival rate. For example for localized NM,
NHWs and Blacks have survival rates 80.6 and 63.9 %,
respectively. However, after adjusting for confounders,
racial differences are significant only for regional and
distant NOS, with Blacks having the lowest survival
rates. Multiple factors contribute to melanoma progno-
sis. Published studies have suggested potential prog-
nostic roles of lesion thickness, ulceration, lymph node
involvement, age, gender, anatomic site, satellite lesion,
serum lactic dehydrogenase (LDH), and others. The
differences in patients’ characteristics, as previously
described, can contribute to survival difference. In
addition, the aforementioned prognostic factors may
also interact with race (for example the distribution of
LDH varies across races [30]). Racial differences in
survival have been examined in the literature. For
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example, Collins and others found that both overall
and melanoma-specific survival was lower in Blacks
undergoing surgical treatment compared to Whites and
other races [5]. However, reasons for these differences
remain poorly understood. Several possible explana-
tions have been raised. For example, compared to
Whites, Blacks were more likely to be diagnosed at
more advanced stages [16, 31]. They were also more
likely to have tumor ulceration, satellite nodules, and
regional and distant metastases [3, 32–35]. Studies have
also suggested that factors not measured in SEER, such
as socioeconomic status, skin cancer awareness, and
cultural and social values, may be related to racial dif-
ferences in survival. Multiple genetic risk factors have
also been suggested as having independent contribu-
tions to survival [36]. However, their interactions with
race have not been examined.
Limitations
The SEER database is analyzed as it is the most com-
prehensive cancer registry in the U.S. However, it has
limitations. The most significant limitation is a lack of
certain important measurements, such as UV exposure,
socioeconomic status, lifestyle, and genetic risk factors.
In addition, the treatment information is also not
complete: there is no information on chemotherapy,
biologic therapy, and others. Connecting to other data-
bases or more data collection are needed. This study
may also have been hindered by the multiple coexisting
classification schemes. Patients diagnosed before 2001
may have diagnosis codes from earlier ICD-O versions
that need to be converted to ICD-O-3, which may have
resulted in unclassified cases. SEER has multiple sites,
and errors may arise in tumor classification and staging.
However, we do not expect systematic errors correlated
with race. The SEER population have a higher propor-
tion of foreign-born patients than the general U.S.
population. Combined with the fact that SEER is lim-
ited to the U.S. only, there may be concerns on the
generalizability of findings.
Conclusions
This epidemiologic study has provided comprehensive
descriptive statistics on racial differences in multiple
aspects of major melanoma subtypes. Similar to many
published studies of the same kind, it cannot reveal the
underlying mechanisms that cause racial differences.
However, it has been shown repeatedly in the literature
that this kind of studies has extensive values. A major
advancement of this study is its comprehensiveness: six
subtypes are analyzed on the same ground, their pat-
terns are compared, and multiple aspects of the disease
are studied.
The analysis of SEER data suggests that racial differ-
ences exist among the six major subtypes of melanoma
in the U.S. in terms of patients’ clinicopathologic char-
acteristics, incidence, treatment, and survival. The
observed differences vary across subtypes. Some plaus-
ible causes of such differences are provided. SEER data
may be limited by lacking certain important informa-
tion. More comprehensive data collection is needed to
fully decipher the racial differences. Despite certain limita-
tions, the findings of this study can be important for early
detection, risk stratification, proper treatment selection,
and elimination of racial disparities in melanoma.
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